10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2011 | |||
Consolidated Statement of Income | |||
Period Ending Dec 31, 2011 10-K (Filed: Feb 28, 2012) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | |
| Sales | $ 48,047 | 45,987 | 27,428 |
| Costs, Expenses and Other | |||
| Materials and production | 16,871 | 18,396 | 9,019 |
| Marketing and administrative | 13,733 | 13,125 | 8,543 |
| Research and development | 8,467 | 11,111 | 5,845 |
| Restructuring costs | 1,306 | 985 | 1,634 |
| Equity income from affiliates | (610) | (587) | (2,235) |
| Other (income) expense, net | 946 | 1,304 | (10,668) |
| Total Costs, Expenses and Other | 40,713 | 44,334 | 12,138 |
| Income before taxes | 7,334 | 1,653 | 15,290 |
| Taxes on Income | 942 | 671 | 2,268 |
| Net Income | 6,392 | 982 | 13,022 |
| Less: Net Income Attributable to Noncontrolling Interests | 120 | 121 | 123 |
| Net Income Attributable to Merck & Co., Inc. | 6,272 | 861 | 12,899 |
| Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | 2.04 | 0.28 | 5.67 |
| Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | 2.02 | 0.28 | 5.65 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2011 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2011 10-K (Filed: Feb 28, 2012) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | |
| Cash Flows from Operating Activities | |||
| Net income | $ 6,392 | 982 | 13,022 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 7,427 | 7,381 | 2,576 |
| Intangible asset impairment charges | 705 | 2,441 | |
| Gain on disposition of interest in equity method investment | (136) | (3,163) | |
| Gain on AstraZeneca LP asset option exercise | (443) | ||
| Gain related to Merck/Schering-Plough partnership | (7,530) | ||
| Equity income from affiliates | (610) | (587) | (2,235) |
| Dividends and distributions from equity affiliates | 216 | 324 | 1,724 |
| Deferred income taxes | (1,537) | (1,092) | 1,821 |
| Share-based compensation | 369 | 509 | 415 |
| Other | 323 | 377 | (535) |
| Net changes in assets and liabilities: | |||
| Accounts receivable | (1,168) | (1,089) | 165 |
| Inventories | (678) | 1,990 | 1,211 |
| Trade accounts payable | 182 | 124 | (45) |
| Accrued and other current liabilities | 1,444 | 35 | (4,003) |
| Income taxes payable | (277) | 128 | (365) |
| Noncurrent liabilities | (7) | (98) | 231 |
| Other | (262) | (160) | 103 |
| Net Cash Provided by Operating Activities | 12,383 | 10,822 | 3,392 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (1,723) | (1,678) | (1,461) |
| Purchases of securities and other investments | (7,325) | (7,197) | (3,071) |
| Proceeds from sales of securities and other investments | 6,149 | 4,561 | 10,942 |
| Proceeds from sale of interest in equity method investment | 175 | 4,000 | |
| Acquisitions of businesses, net of cash acquired | (373) | (256) | (130) |
| Dispositions of businesses, net of cash divested | 323 | ||
| Schering-Plough merger, net of cash acquired | (12,843) | ||
| Proceeds from AstraZeneca LP asset option exercise | 647 | ||
| Decrease in restricted assets | 276 | 5,548 | |
| Other | (116) | 150 | 171 |
| Net Cash (Used in) Provided by Investing Activities | (2,890) | (3,497) | 3,156 |
| Cash Flows from Financing Activities | |||
| Net change in short-term borrowings | 1,076 | 90 | (2,422) |
| Payments on debt | (1,547) | (1,341) | (25) |
| Proceeds from issuance of debt | 1,999 | 4,228 | |
| Purchases of treasury stock | (1,921) | (1,593) | |
| Dividends paid to stockholders | (4,691) | (4,734) | (3,215) |
| Other dividends paid | (120) | (119) | (264) |
| Proceeds from exercise of stock options | 321 | 363 | 186 |
| Other | (22) | (106) | (126) |
| Net Cash Used in Financing Activities | (6,904) | (5,441) | (1,638) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 42 | (295) | 33 |
| Net Increase in Cash and Cash Equivalents | 2,631 | 1,589 | 4,943 |
| Cash and Cash Equivalents at Beginning of Year | 10,900 | 9,311 | |
| Cash and Cash Equivalents at End of Year | 13,531 | 10,900 | 9,311 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
MERCK & CO., INC. | ||
Ticker: MRK Fiscal Year: 2011 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2011 10-K (Filed: Feb 28, 2012) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2011 | Dec 31, 2010 | |
| Assets | ||
| Current Assets | ||
| Cash and cash equivalents | $ 13,531 | 10,900 |
| Short-term investments | 1,441 | 1,301 |
| Accounts receivable (net of allowance for doubtful accounts of $131 in 2011 and $104 in 2010) | 8,261 | 7,344 |
| Inventories (excludes inventories of $1,379 in 2011 and $1,194 in 2010 classified in Other assets - see Note 8) | 6,254 | 5,868 |
| Deferred income taxes and other current assets | 3,694 | 3,651 |
| Total current assets | 33,181 | 29,064 |
| Investments | 3,458 | 2,175 |
| Property, Plant and Equipment (at cost) | ||
| Land | 623 | 658 |
| Buildings | 12,733 | 11,945 |
| Machinery, equipment and office furnishings | 16,919 | 15,894 |
| Construction in progress | 2,198 | 2,066 |
| Property, Plant and Equipment, Gross | 32,473 | 30,563 |
| Less: accumulated depreciation | 16,176 | 13,481 |
| Property, Plant and Equipment, Net, Total | 16,297 | 17,082 |
| Goodwill | 12,155 | 12,378 |
| Other Intangibles, Net | 34,302 | 39,456 |
| Other Assets | 5,735 | 5,626 |
| Total Assets | 105,128 | 105,781 |
| Liabilities and Equity | ||
| Current Liabilities | ||
| Loans payable and current portion of long-term debt | 1,990 | 2,400 |
| Trade accounts payable | 2,462 | 2,308 |
| Accrued and other current liabilities | 9,731 | 8,514 |
| Income taxes payable | 781 | 1,243 |
| Dividends payable | 1,281 | 1,176 |
| Total current liabilities | 16,245 | 15,641 |
| Long-Term Debt | 15,525 | 15,482 |
| Deferred Income Taxes and Noncurrent Liabilities | 16,415 | 17,853 |
| Merck & Co., Inc. Stockholders' Equity | ||
| Common stock, $0.50 par value, Authorized - 6,500,000,000 shares Issued - 3,576,948,356 shares in 2011 and 2010 | 1,788 | 1,788 |
| Other paid-in capital | 40,663 | 40,701 |
| Retained earnings | 38,990 | 37,536 |
| Accumulated other comprehensive loss | (3,132) | (3,216) |
| Stockholders' equity before deduction for treasury stock | 78,309 | 76,809 |
| Less treasury stock, at cost : 536,109,713 shares in 2011 and 494,841,533 shares in 2010 | 23,792 | 22,433 |
| Total Merck & Co., Inc. stockholders' equity | 54,517 | 54,376 |
| Noncontrolling Interests | 2,426 | 2,429 |
| Total equity | 56,943 | 56,805 |
| Liabilities and Equity | 105,128 | 105,781 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2011 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |